<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chemotherapy response in different histologies of salivary gland tumors</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chemotherapy response in different histologies of salivary gland tumors</h1>
<div class="graphic"><div class="figure"><div class="ttl">Chemotherapy response in different histologies of salivary gland tumors</div><div class="cntnt"><table cellspacing="0"><tbody> <tr> <td class="subtitle1" rowspan="3">Agent/regimen</td> <td class="subtitle1" colspan="3">Histology</td> </tr> <tr> <td class="subtitle2">Adenoid cystic cancer</td> <td class="subtitle2">Mucoepidermoid cancer</td> <td class="subtitle2">Adenocarcinoma</td> </tr> <tr> <td class="subtitle3">Number of responses/total number of patients (%)</td> <td class="subtitle3">Number of responses/total number of patients (%)</td> <td class="subtitle3">Number of responses/total number of patients (%)</td> </tr> <tr> <td>Cisplatin<sup>[1,2]</sup></td> <td>2/32 (6)</td> <td>1/5</td> <td>0/5</td> </tr> <tr> <td>Vinorelbine<sup>[3]</sup></td> <td>2/13 (15)</td> <td>-</td> <td>2/5</td> </tr> <tr> <td>Mitoxantrone<sup>[4,5]</sup></td> <td>5/50 (10)</td> <td>-</td> <td>-</td> </tr> <tr> <td>Epirubicin<sup>[6]</sup></td> <td>2/20 (10)</td> <td>-</td> <td>-</td> </tr> <tr> <td>Methotrexate<sup>[7]</sup></td> <td>-</td> <td>2/5 (40)</td> <td>-</td> </tr> <tr> <td>Paclitaxel<sup>[8]</sup></td> <td>0/14</td> <td>3/14 (21)</td> <td>5/17 (29)</td> </tr> <tr> <td>CAP or CAP/FU<sup>[7,9-14]</sup></td> <td>12/43 (28)</td> <td>5/6 (83)</td> <td>23/37 (62)</td> </tr> <tr> <td>Cisplatin/anthracycline ± FU<sup>[15-18]</sup></td> <td>6/19 (32)</td> <td>1/4</td> <td>8/14 (57)</td> </tr> <tr> <td>Cyclophosphamide/doxorubicin<sup>[7,19]</sup></td> <td>2/6</td> <td>0/6</td> <td>1/1</td> </tr> <tr> <td>Cisplatin/MTX/bleomycin<sup>[7,19]</sup></td> <td>0/3</td> <td>2/3 (66)</td> <td>-</td> </tr> <tr> <td>Cisplatin/FU<sup>[20]</sup></td> <td>0/11</td> <td>-</td> <td>-</td> </tr> <tr> <td>Cisplatin/vinorelbine<sup>[3]</sup></td> <td>4/9 (44)</td> <td>-</td> <td>1/5</td> </tr> <tr> <td>Cisplatin/doxorubicin/bleomycin<sup>[2]</sup></td> <td>3/9 (33)</td> <td>-</td> <td>-</td> </tr> <tr> <td>Carboplatin/paclitaxel<sup>[21,22]</sup></td> <td>2/10 (20)</td> <td>-</td> <td>1/1</td> </tr> <tr> <td>Cisplatin/gemcitabine<sup>[23]</sup></td> <td>2/10 (20)</td> <td>1/4 (25)</td> <td>3/8 (38)</td> </tr> </tbody></table></div><div class="graphic_footnotes">CAP: cyclophosphamide, doxorubicin, cisplatin; FU: fluorouracil; MTX: methotrexate.</div><div class="graphic_reference">References:<br/><ol>
<li>Licitra L, Marchini S, Spinazzè S, et al. Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients. Cancer 1991; 68:1874. </li>
<li>de Haan LD, De Mulder PH, Vermorken JB, et al. Cisplatin-based chemotherapy in advanced adenoid cystic carcinoma of the head and neck. Head Neck 1992; 14:273. </li>
<li>Airoldi M, Pedani F, Succo G, et al. Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. Cancer 2001; 91:541. </li>
<li>Mattox DE, Von Hoff DD, Balcerzak SP. Southwest Oncology Group study of mitoxantrone for treatment of patients with advanced adenoid cystic carcinoma of the head and neck. Invest New Drugs 1990; 8:105. </li>
<li>Verweij J, de Mulder PH, de Graeff A, et al. Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck. EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 1996; 7:867. </li>
<li>Vermorken JB, Verweij J, de Mulder PH, et al. Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 1993; 4:785. </li>
<li>Kaplan MJ, Johns ME, Cantrell RW. Chemotherapy for salivary gland cancer. Otolaryngol Head Neck Surg 1986; 95:165. </li>
<li>Gilbert J, Li Y, Pinto HA, et al. Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group. Head Neck 2006; 28:197. </li>
<li>Licitra L, Cavina R, Grandi C, et al. Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients. Ann Oncol 1996; 7:640. </li>
<li>Dreyfuss AI, Clark JR, Fallon BG, et al. Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin. Cancer 1987; 60:2869. </li>
<li>Creagan ET, Woods JE, Rubin J, Schaid DJ. Cisplatin-based chemotherapy for neoplasms arising from salivary glands and contiguous structures in the head and neck. Cancer 1988; 62:2313. </li>
<li>Belani CP, Eisenberger MA, Gray WC. Preliminary experience with chemotherapy in advanced salivary gland neoplasms. Med Pediatr Oncol 1988; 16:197. </li>
<li>Dimery IW, Legha SS, Shirinian M, Hong WK. Fluorouracil, doxorubicin, cyclophosphamide, and cisplatin combination chemotherapy in advanced or recurrent salivary gland carcinoma. J Clin Oncol 1990; 8:1056. </li>
<li>Alberts DS, Manning MR, Coulthard SW, et al. Adriamycin/cis-platinum/cyclophosphamide combination chemotherapy for advanced carcinoma of the parotid gland. Cancer 1981; 47:645. </li>
<li>Airoldi M, Pedani F, Brando V, et al. Cisplatin, epirubicin and 5-fluorouracil combination chemotherapy for recurrent carcinoma of the salivary gland. Tumor 1989; 75:252. </li>
<li>Venook AP, Tseng A Jr, Meyers FJ, et al. Cisplatin, doxorubicin, and 5-fluorouracil chemotherapy for salivary gland malignancies: a pilot study of the Northern California Oncology Group. J Clin Oncol 1987; 5:951. </li>
<li>Tsukuda M, Kokatsu T, Ito K, et al. Chemotherapy for recurrent adeno- and adenoidcystic carcinomas in the head and neck. J Cancer Res Clin Oncol 1993; 119:756. </li>
<li>White JD, Junor EJ, McGarva J, et al. Adenocarcinoma of the salivary gland? A chemo-sensitive disease. Clin Oncol 2004; 16:159. </li>
<li>Posner MR, Ervin TJ, Weichselbaum RR, et al. Chemotherapy of advanced salivary gland neoplasms. Cancer 1982; 50:2261. </li>
<li>Hill ME, Constenla DO, A'Hern RP, et al. Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma. Oral Oncol 1997; 33:275. </li>
<li>Ruzich JC, Ciesla MC, Clark JI. Response to paclitaxel and carboplatin in metastatic salivary gland cancer: a case report. Head Neck 2002; 24:406. </li>
<li>Airoldi M, Fornari G, Pedani F, et al. Paclitaxel and carboplatin for recurrent salivary gland malignancies. Anticancer Res 2000; 20:3781. </li>
<li>Laurie SA, Siu LL, Winquist E, et al. A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer: a trial of the NCIC Clinical Trials Group. Cancer 2010; 116:362. </li></ol></div><div id="graphicVersion">Graphic 81091 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
